Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merck & Co Inc (NYSE:MRK)

56.26
Delayed Data
As of May 31
 -0.22 / -0.39%
Today’s Change
45.69
Today|||52-Week Range
61.70
+6.51%
Year-to-Date
MRK, SHPG And JNJ, Pushing Drugs Industry Downward
May 31 / TheStreet.com - Paid Partner Content
Cancer Immunotherapies Take Center Stage in Pre-ASCO Abstract Releases
May 26 / MotleyFool.com - Paid Partner Content
Pharmacy Benefit Managers Drift Upware Amid Antitrust Worries
May 31 / TheStreet.com - Paid Partner Content
Market Indexes Higher With Volatility Lower
May 25 / GuruFocus News - Paid Partner Content
Gilead's (GILD) New HCV Drug Epclusa Wins CHMP Backing
May 31 / Zacks.com - Paid Partner Content
Billionaires Are Bailing on Gilead Sciences -- Should You, Too?
May 25 / MotleyFool.com - Paid Partner Content
Merck, AbbVie & Amgen Drugs a Step Closer to EU Approval
May 31 / Zacks.com - Paid Partner Content
Calpers seeks more access to Exxon's board
May 24 / FT.com - Paid Partner Content
These 5 Big Pharma Stocks Are Ridiculously Cheap
May 30 / MotleyFool.com - Paid Partner Content
Will These Game-Changing Cancer Treatments Hit the Market in 2016?
May 19 / MotleyFool.com - Paid Partner Content
3 Dividend Growth Stocks to Buy in June
May 29 / MotleyFool.com - Paid Partner Content
Multibillion-dollar pharma levy proposed in superbugs battle
May 18 / FT.com - Paid Partner Content
Merck Gets Favorable Opinion From CHMP For Its ZEPATIER
May 27 / Benzinga - Paid Partner Content
Pfizer to trial triple-combination cancer treatment
May 09 / FT.com - Paid Partner Content